Furthermore, TRAIL death receptor 2 is overexpressed in KRAS-mutated tumors, and this overexpression activates the Rac1/PI3K pathway, which in turn promotes KRAS-driven tumor progression, invasion, and metastasis [71]. This evidence concerns the gene KRAS and neoplasm.